Literature DB >> 2179926

Cholinergic dysfunction in depression.

D S Janowsky1, D H Overstreet.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2179926     DOI： 10.1111/j.1600-0773.1990.tb02077.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN： 0901-9928


× No keyword cloud information.
  14 in total

1.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

2.  Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.

Authors:  Jessica S Ellis; Carlos A Zarate; David A Luckenbaugh; Maura L Furey
Journal:  J Affect Disord       Date:  2014-03-26       Impact factor: 4.839

3.  No evidence for association between 19 cholinergic genes and bipolar disorder.

Authors:  Jiajun Shi; Eiji Hattori; Hongwei Zou; Judith A Badner; Susan L Christian; Elliot S Gershon; Chunyu Liu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-09-05       Impact factor: 3.568

4.  Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice.

Authors:  Yann S Mineur; Matthew P Bentham; Wen-Liang Zhou; Margreet E Plantenga; Sherry A McKee; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2015-07-07       Impact factor: 4.530

5.  A genetic survey of fluoxetine action on synaptic transmission in Caenorhabditis elegans.

Authors:  Andrey Kullyev; Catherine M Dempsey; Sarah Miller; Chih-Jen Kuan; Vera M Hapiak; Richard W Komuniecki; Christine T Griffin; Ji Ying Sze
Journal:  Genetics       Date:  2010-08-25       Impact factor: 4.562

6.  Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors:  Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

7.  IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression.

Authors:  Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Frank N M Twisk; Michel Geffard
Journal:  Metab Brain Dis       Date:  2012-05-22       Impact factor: 3.584

Review 8.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

Review 9.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 10.  Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors.

Authors:  Marina R Picciotto; Christian Brabant; Emily B Einstein; Helen M Kamens; Nichole M Neugebauer
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.